Successful treatment of Aspergillus ventriculitis through voriconazole adaptive pharmacotherapy, immunomodulation, and therapeutic monitoring of cerebrospinal fluid (1→3)-β-D-glucan

Tempe K. Chen, Paula K. Groncy, Ramin Javahery, Richard Y. Chai, Pablito Nagpala, Malcolm Finkelman, Ruta Petraitiene, Thomas J. Walsh

Research output: Contribution to journalArticle

Abstract

Aspergillus ventriculitis is an uncommon but often fatal form of invasive aspergillosis of the central nervous system (CNS). As little is known about the diagnosis, treatment, and outcome of this potentially lethal infection, we report the strategies used to successfully treat Aspergillus ventriculitis complicating a pineal and pituitary germinoma with emphasis on the critical role of adaptive pharmacotherapy of voriconazole and serial monitoring of (1→3)-β-D-glucan in cerebrospinal fluid. We describe several rationally based therapeutic modalities, including adaptive pharmacotherapy, combination therapy, sargramostim-based immunomodulation, and biomarker-based therapeutic monitoring of the CNS compartment. Through these strategies, our patient remains in remission from both his germinoma and Aspergillus ventriculitis making him one of the few survivors of Aspergillus ventriculitis.

Original languageEnglish (US)
Pages (from-to)109-117
Number of pages9
JournalMedical Mycology
Volume55
Issue number1
DOIs
StatePublished - 2017

Keywords

  • (1→3)-β-D-glucan
  • Aspergillus
  • Central nervous system (CNS)
  • Cerebrospinal fluid (CSF)
  • Voriconazole

ASJC Scopus subject areas

  • veterinary(all)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Successful treatment of Aspergillus ventriculitis through voriconazole adaptive pharmacotherapy, immunomodulation, and therapeutic monitoring of cerebrospinal fluid (1→3)-β-D-glucan'. Together they form a unique fingerprint.

  • Cite this